These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 31907434)

  • 1. Immune agonist antibodies face critical test.
    Garber K
    Nat Rev Drug Discov; 2020 Jan; 19(1):3-5. PubMed ID: 31907434
    [No Abstract]   [Full Text] [Related]  

  • 2. The promise and challenges of immune agonist antibody development in cancer.
    Mayes PA; Hance KW; Hoos A
    Nat Rev Drug Discov; 2018 Jul; 17(7):509-527. PubMed ID: 29904196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint inhibitors: outstanding efficacy but at what cost?
    Klastersky JA
    Curr Opin Oncol; 2016 Jul; 28(4):253. PubMed ID: 27163724
    [No Abstract]   [Full Text] [Related]  

  • 4. Releasing the Brakes on Cancer Immunotherapy.
    Ribas A
    N Engl J Med; 2015 Oct; 373(16):1490-2. PubMed ID: 26348216
    [No Abstract]   [Full Text] [Related]  

  • 5. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.
    Hahn AW; Gill DM; Pal SK; Agarwal N
    Immunotherapy; 2017 Jun; 9(8):681-692. PubMed ID: 28653573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer immunotherapy in patients with preexisting autoimmune disorders.
    Donia M; Pedersen M; Svane IM
    Semin Immunopathol; 2017 Apr; 39(3):333-337. PubMed ID: 27730287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunotherapy comes of age and looks for maturity.
    Finck A; Gill SI; June CH
    Nat Commun; 2020 Jul; 11(1):3325. PubMed ID: 32620755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Regulatory T cells in cancer immunotherapy].
    Nishikawa H
    Rinsho Ketsueki; 2014 Oct; 55(10):2183-9. PubMed ID: 25297785
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial: Is the Recent Burst of Therapeutic Anti-tumor Antibodies the Tip of an Iceberg?
    Kremer L; Garcia-Sanz JA
    Front Immunol; 2018; 9():442. PubMed ID: 29556241
    [No Abstract]   [Full Text] [Related]  

  • 10. Hiding in Plain Sight: Soluble Immunomodulatory Receptors.
    Dahal LN; Schwarz H; Ward FJ
    Trends Immunol; 2018 Oct; 39(10):771-774. PubMed ID: 30195467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Not Available].
    Caux C; Bay JO
    Bull Cancer; 2018 Dec; 105 Suppl 1():S1-S2. PubMed ID: 30595190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors for Urologic Cancer: The Tip of the Iceberg?
    Powles T
    Eur Urol; 2015 Aug; 68(2):280-2. PubMed ID: 25800945
    [No Abstract]   [Full Text] [Related]  

  • 13. New checkpoint inhibitors ride the immunotherapy tsunami.
    Mullard A
    Nat Rev Drug Discov; 2013 Jul; 12(7):489-92. PubMed ID: 23812256
    [No Abstract]   [Full Text] [Related]  

  • 14. [Immune-checkpoints: the new anti-cancer immunotherapies].
    Ileana E; Champiat S; Soria JC
    Bull Cancer; 2013 Jun; 100(6):601-10. PubMed ID: 23735730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Immunotargets and Immunotherapies in Prostate Cancer.
    Montironi R; Santoni M; Sotte V; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Berardi R; Scarpelli M
    Curr Drug Targets; 2016; 17(7):777-82. PubMed ID: 26898309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer treatment: The killer within.
    Ledford H
    Nature; 2014 Apr; 508(7494):24-6. PubMed ID: 24695297
    [No Abstract]   [Full Text] [Related]  

  • 17. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical autoimmune adverse effects with checkpoint blockade therapies.
    Friedman CF; Snyder A
    Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
    [No Abstract]   [Full Text] [Related]  

  • 19. Vaccines versus immunotherapy: overview of approaches in deciding between options.
    Dalgleish AG
    Hum Vaccin Immunother; 2014; 10(11):3369-74. PubMed ID: 25625932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing immune checkpoints for cancer therapy.
    Vinay DS; Kwon BS
    Immunotherapy; 2018 Oct; 10(14):1265-1284. PubMed ID: 30326786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.